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Background: Acute respiratory distress syndrome (ARDS) is a potentially fatal disease with high mortality. Our aim
was to summarize the current evidence for use of neuromuscular blocking agents (NMBA) in the early phase of
ARDS.
Methods: Systematic review and meta-analysis of publications between 1966 and 2012. The Medline and CENTRAL
databases were searched for studies on NMBA in patients with ARDS. The meta-analysis was limited to: 1)
randomized controlled trials; 02) adult human patients with ARDS or acute lung injury; and 03) use of any NMBA in
one arm of the study compared with another arm without NMBA. The outcomes assessed were: overall mortality,
ventilator-free days, time of mechanical ventilation, adverse events, changes in gas exchange, in ventilator settings,
and in respiratory mechanics.
Results: Three randomized controlled trials covering 431 participants were included. Patients treated with NMBA
showed less mortality (Risk ratio, 0.71 [95 % CI, 0.55 – 0.90]; number needed to treat, 1 – 7), more ventilator free
days at day 28 (p= 0.020), higher PaO2 to FiO2 ratios (p= 0.004), and less barotraumas (p= 0.030). The incidence of
critical illness neuromyopathy was similar (p= 0.540).
Conclusions: The use of NMBA in the early phase of ARDS improves outcome.
Keywords: ARDS, Neuromuscular blocking agents, Meta-analysis, ReviewBackground
Acute respiratory distress syndrome (ARDS) is a poten-
tially fatal disease with high mortality even with the use
of protective ventilation strategy [1]. Several therapies
were tested in patients with ARDS like prone position-
ing, corticosteroids, inhalation of nitric oxide, high fre-
quency oscillatory ventilation, recruitment maneuvers
and, in the most severe cases, extracorporeal membrane
oxygenation (ECMO) [2].
Recently, Papazian et al [3] showed that the use of a
neuromuscular blocking agent (NMBA) early in the
course of ARDS improves the overall survival and* Correspondence: aryserpa@terra.com.br
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in any medium, provided the original work is pincreases the time off the ventilator. This study has some
limitations as: 01) patients who are not paralyzed can
trigger the ventilator and paralyzed patients cannot so,
adequate blinding would seen to have been nearly im-
possible; 02) the neuromuscular blockade was not
assessed by the train-of-fours; and 03) the assessment of
muscle weakness had some limitations. Current guide-
lines indicate that NMBA are appropriate for facilitating
mechanical ventilation when sedation alone is inad-
equate, most notably in patients with severe gas-
exchange impairments, like in patients with ARDS [4].
The potential use of NMBA in patients with ARDS
was tested in a few randomized controlled trials. In front
of the limitations of the larger study in this field we con-
ducted a systematic review and meta-analysis of theOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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the use of NMBA in patients with ARDS.
Methods
Literature search and data extraction
The online database of MedLine (1966 – 2012) and
Cochrane Register of Controlled Trials were searched
for studies that fulfill the following inclusion criteria: 1)
randomized controlled trials; 02) adult human patients
(age> 18 years) with ARDS or acute lung injury (AECC
criteria in the first 48 hours); [5] and 03) use of any
NMBA in one arm of the study compared with another
arm without NMBA. There is no language restriction.
The following terms were combined in the search
strategy: (acute respiratory distress syndrome [MeSH]
OR acute lung injury [MeSH]) AND (neuromuscular
blocking agents [MeSH] OR neuromuscular blockade
[MeSH] OR vecuronium bromid [MeSH] OR atracurium
[MeSH] OR cisatracurium [MeSH] OR pancuronium
[MeSH] OR rocuronium [MeSH]). When we found du-
plicate reports of the same study in preliminary abstracts
and articles, we analyzed data from the most complete
data set.
Data were independently extracted from each report
by three authors, using a data recording form developed
for this purpose. After extraction, data were reviewed
and compared by the first author. Instances of disagree-
ment between the two other extractors were solved by aFigure 1 Literature search strategy.consensus among the investigators. The quality of each
study was assessed as suggested by the Grading of
Recommendation Assessment Development and Evalu-
ation Working Group (GRADE). Also, we used the
GRADE approach to summarize the quality of evidence
for each outcome [6].
Outcomes and data analysis
The primary outcome was overall mortality in patients
treated with NMBA vs. patients not treated with NMBA.
The secondary outcomes included: ventilator free days,
duration of mechanical ventilation, adverse events (baro-
trauma and neuromyopathy), changes in gas exchange
(PaCO2, PaO2 / FiO2), ventilatory settings (PEEP, FiO2,
tidal volume), and respiratory mechanics (plateau
pressure).
We extracted data regarding the study design, patient
characteristics, overall survival, time to extubation, inci-
dence of adverse events, and mean change in arterial
blood gases. For the analysis of survival, we calculated a
pooled estimate of risk ratio (RR) in the individual stud-
ies using a fixed effect model according to Mantel and
Haenszel and graphically represented these results using
forest plot graphs. For continuous variables, we used the
standardized mean difference (SMD) which is the differ-
ence in means divided by a standard deviation. The
homogeneity assumption was checked by a χ [2] test with
a df equal to the number of analyzed studies minus 1.
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v.5.1.1 and SPSS v.16.0.1. The Summary of Findings
(SoF) tables were created in GRADEpro 3.6. For all ana-
lyses p values< .05 were considered significant.
Results
The comprehensive literature search yielded 60 refer-
ences, of which 46 articles were excluded during the first
screening, which was based on abstracts or titles, leaving
14 articles for full text review. During this review, 11
articles were excluded for the following reasons: letter to
editor (n = 5); non-randomized trial (n = 3); review article
(n = 2); and case report (n = 1). Finally, three articles (431
participants) were included in the final analysis [3,7,8]
(Figure 1).
All three studies analyzed were randomized controlled
trials and uses placebo in the control arm. All threeTable 1 Characteristics of the studies included
Characteristics Gainnier M, 20047
NMBA Control
Number of centers Four
Number of participants 28 28
Age, years 59.8 ± 17.5 61.5 ± 14.6
Lung injury score 2.89 ± 0.40 2.93 ± 0.42
SAPS II 41.8 ± 10.4 45.4 ± 10.5
Drug used Cistracurium Placebo
Sedation strategy Ramsay 6* Ramsay 6*
Assessment of blockade TOF None
Maximal time to randomization, hours 36 36
Time with NMBA, hours 48
Onset of ARDS, days 0.96 ± 0.79 1.14 ± 1.72
Days receiving mechanical ventilation 2.7 ± 2.6 3.4 ± 3.5
Baseline PaO2 / FiO2 130 ± 34 119 ± 31
Baseline PaCO2, mmHg 48.3 ± 9.0 47.4 ± 11.2
Baseline PEEP, cmH2O 11.1 ± 2.8 10.9 ± 2.4
Baseline VT, mL/kg 7.1 ± 1.1 7.4 ± 1.9
Baseline FiO2, % 70.2 ± 17.0 67.3 ± 15.8
Baseline Plateau pressure, cmH2O 27.1 ± 6.2 26.1 ± 4.0
Time of assessment of oxygenation, hours 120 120
Duration of mechanical ventilation, days 20.9 ± 15.0 21.2 ± 17.4
Ventilator-free days at day 28, days 3.7 ± 7.2 1.7 ± 5.3
Barotrauma, n (%) 0 (0.0) 1 (3.5)
Critical illness neuromyopathy, n (%) 0 (0.0) 0 (0.0)
ICU mortality, n (%) 13 (46.4) 20 (71.4)
Mortality at day 28 after inclusion, n (%) 10 (37.5) 17 (60.7)
NMBA: Neuromuscular blocking agents; SAPS: Simplified acute physiology score; AR
pressure; VT: Tidal volume; FiO2: Fraction of inspired oxygen; ICU: Intensive care uni
*: Midazolam + Sufentanil.
**: p ≤ 0.05.studies used cisatracurium during 48 hours for myore-
laxation, and two studies assessed neuromuscular block-
ade with the train-of-four [6,7]. The mean follow-up for
the assessment of gas exchange was 136.00 ± 27.71
hours. Characteristics of the studies analyzed are show
in Table 1 and the study quality assessment is show in
Table 2.
Seventy out of 223 patients (31.4 %) assigned to neuro-
muscular blockade and 93 out of 208 patients (44.7 %)
assigned as controls died during ICU stay (Risk ratio
[RR], 0.71 [95 % CI, 0.55 – 0.90]; number needed to treat
[NNT], 1 – 7). After analyzed 385 patients from two
studies [3,7], this finding was similar after 28 days of
follow-up (RR, 0.69 [95 % CI, 0.51 – 0.92]; NNT, 1 – 8).
Patients treated with NMBA needed less days of mech-
anical ventilation with a higher number of ventilator-
free days at day 28 (p= 0.0020). At the final of follow-up,Forel JM, 20068 Papazian L, 20103
NMBA Control NMBA Control
Three Twenty
18 18 177 162
52.0 ± 16.0 61.0 ± 18.0 58.0 ± 16.0 58 ± 15.0
3.0 ± 0.2 2.8 ± 0.4 — —
47.0 ± 15.0 49.0 ± 19.0 50.0 ± 16.0 47.0 ± 14.0
Cistracurium Placebo Cisatracurium Placebo
Ramsay 6* Ramsay 6* Ramsay 6* Ramsay 6*
TOF None None None
48 48 48 48
48 48
1.0 ± 0.8 1.2 ± 0.8 0.75 ± 0.41 0.62 ± 0.32
— — 0.91 ± 0.87 0.87 ± 0.74
105 ± 22 125 ± 20 106.0 ± 36.0 115.0 ± 41.0**
51.1 ± 9.9 47.2 ± 9.8 47.0 ± 11.0 47.0 ± 11.0
13.2 ± 2.7 11.0 ± 2.7 9.2 ± 3.2 9.2 ± 3.5
6.5 ± 0.7 7.0 ± 0.7 6.55 ± 1.12 6.48 ± 0.92
80.0 ± 15.0 71.0 ± 19.0 79.0 ± 19.0 77.0 ± 22.0
27.5 ± 4.4 24.8 ± 5.7 25.0 ± 5.1 24.4 ± 4.7
120 120 168 168
20.0 ± 11.6 18.0 ± 8.3 — —
6.0 ± 8.6 5.4 ± 6.4 10.6 ± 9.7 8.5 ± 9.4**
1 (0.0) 1 (0.0) 9 (5.0) 19 (11.7)**
1 (5.5) 1 (5.5) 40 (35.7) 28 (36.3)
5 (27.8) 10 (55.6) 52 (29.3) 63 (38.8)
— — 42 (23.7) 54 (33.3)**
DS: Acute respiratory distress syndrome; PEEP: Positive end expiratory
t; TOF: train-of-fours.
Table 2 Assessment of study quality
Studies Allocation Concealment Blinding ITT Analysis Lost to Follow-up Early Stopping Baseline similarity
Gainnier M, 2004 Yes (Not specified) Yes Yes No No Yes
Forel JM, 2006 Yes (Not specified) Yes No No No Yes
Papazian L, 2010 Yes (Computer generated) Yes Yes No No Yes
ITT: Intention-to-treat.
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PaO2 to FiO2 ratio (p= 0.004), at lower FiO2 (p= 0.002).
The incidence of barotrauma was lower in patients
under neuromuscular blockade (p= 0.030) while the in-
cidence of critical illness neuromyopathy was similar in
both groups (p= 0.540). (Table 3 and Figure 2).
PaCO2 levels, tidal volume, and plateau pressure were
similar in both groups at the final follow-up (p= 0.800,
p= 0.850, and p= 0.250, respectively). There was a trend
to the use of lower PEEP levels in patients under NMBA
(p= 0.060), and even with the same tidal volume,
patients treated with NMBA had lower plateau pressure
at final follow-up, although this not reached significance
(p= 0.250). However, when we assessed the changes of
the variables during the follow-up (last value of the
follow-up – baseline values) we founded a higher de-
crease in PEEP levels (− 2.20 ± 1.90 vs. - 0.46 ± 0.56, for
NMBA and controls, respectively; p= 0.050), and in plat-
eau pressure (− 3.66 ± 1.49 vs. - 0.70 ± 0.60, for NMBA
and controls, respectively; p= 0.050). (Table 3 and 4).Table 3 Baseline characteristics and outcomes of the patients
Cisatracurium Control
(n = 223) (n = 208)
Age, years 56.60 ± 4.08 60.16 ± 1.89
Lung injury score 2.94 ± 0.07 2.86 ± 0.09
SAPS II 46.26 ± 4.14 47.13 ± 1.80
Onset of ARDS, days 0.90 ± 0.13 0.98 ± 0.31
Days receiving mechanical ventilation 1.80 ± 1.26 2.13 ± 1.78
Change in PaO2 / FiO2
* 93.66 ± 40.12 42.66 ± 4.04
Change in PaCO2
*, mmHg 8.76 ± 27.1 10.66 ± 23.80
Change in PEEP*, cmH2O - 2.20 ± 1.90 - 0.46 ± 0.56
Change in VT
*, mL/kg 0.28 ± 0.33 0.30 ± 0.11
Change in FiO2
*, % - 25.40 ± 7.91 - 13.10 ± 7.39
Change in Plateau Pressure*, cmH2O - 3.66 ± 1.49 - 0.70 ± 0.60
Ventilator-free days at day 28, days 6.76 ± 3.51 5.20 ± 3.40
Barotrauma, n (%) 9 (4.0) 20 (9.6)
Critical illness neuromyopathy, n (%) 41 (18.3) 29 (13.9)
ICU mortality, n (%) 70 (31.4) 93 (44.7)
Mortality at day 28 after inclusion, n (%) 52 (23.3) 71 (34.1)
SAPS: Simplified acute physiology score; ARDS: Acute respiratory distress syndrome
inspired oxygen; ICU: Intensive care unit.
* Change in these variables were calculated as follow: (last value of the follow-up) –
** Mann-Whitney Exact Test.
} SMD calculated with the values in the final period of follow-up.One day after the final of infusion (72 hours) patients in
the NMBA group presented a higher increase in PaO2 /
FiO2 ratio and a higher decrease in the plateau pressure
(Table 4 and Figure 3).
In Table 5, the GRADE evidence profile is provided.
This profile evaluates the impact of NMBA in patients
with ARDS.
Discussion
We founded evidence that the use of NMBA in the early
phase of ARDS improves outcome, demonstrated by a
higher overall ICU survival and survival at day 28, a
higher number of ventilator-free days at day 28, an in-
crease in PaO2 to FiO2 ratio, and reduced incidence of
barotrauma when compared with the conventional care.
Notably, the incidence of critical illness neuromyopathy
was similar between patients treated with NMBA and in
controls.
Neuromuscular blocking agents block neuromuscular







0.050** SMD: 0.29 (0.09 – 0.49)} 0.320 0.004
0.150** SMD: 0.02 (-0.17 – 0.21) } 0.520 0.800
0.050** SMD: -0.18 (-0.37 – 0.01) } 0.430 0.060
0.150** SMD: -0.02 (-0.21 – 0.17) } 0.300 0.850
0.050** SMD: -0.31 (-0.50 – -0.12) } 0.260 0.002
0.050** SMD: -0.11 (-0.30 – 0.08) } 0.040 0.250
SMD: 0.22 (0.03 – 0.41) 0.860 0.020
RR: 0.45 (0.22 – 0.92) 0.830 0.030
RR: 1.13 (0.76 – 1.66) 0.990 0.550
RR: 0.71 (0.55 – 0.90) 0.620 0.005
RR: 0.68 (0.51 – 0.92) 0.580 0.010
; PEEP: Positive end expiratory pressure; VT: Tidal volume; FiO2: Fraction of
(baseline value).
Figure 2 Effect of neuromuscular blockade in patients with ARDS at the end of the follow-up period for each study.
Table 4 Difference of physiological variables one day after the final of the NMBA infusion (72 hours)





Cisatracurium Control Cisatracurium Control
(n = 223) (n = 208) (n = 223) (n = 208)
PaO2 / FiO2 113.6 ± 14.1 119.6 ± 5.03 197.3 ± 32.0 165.6 ± 7.50 83.66 ± 35.92 46.00 ± 4.58 0.050
PaCO2, mmHg 48.80 ± 2.09 47.20 ± 0.20 45.43 ± 1.35 44.76 ± 1.59 - 3.36 ± 1.97 - 2.43 ± 1.43 0.658
PEEP, cmH2O 11.16 ± 2.00 10.36 ± 1.01 10.10 ± 0.81 10.50 ± 0.75 - 1.06 ± 1.22 0.13 ± 0.47 0.127
VT, mL/kg 6.71 ± 0.33 6.96 ± 0.46 6.80 ± 0.34 7.00 ± 0.45 0.08 ± 0.02 0.04 ± 0.05 0.246
FiO2, % 76.40 ± 5.39 71.76 ± 4.89 56.00 ± 1.00 59.00 ± 0.00 - 20.40 ± 5.57 - 12.76 ± 4.8 0.127
Positive end expiratory pressure; VT: Tidal volume; FiO2: Fraction of inspired oxygen; ICU: Intensive care unit.
*: Mann-Whitney Exact Test.
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Figure 3 Changes in PaO2 / FiO2 (circles), plateau pressure (triangles) and PEEP (squares) between patients under NMBA (continuous
line and closed symbols) and controls (dashed lines and open symbols).
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http://www.annalsofintensivecare.com/content/2/1/33paralysis of the affected skeletal muscles. The mechan-
ism underlying the beneficial effect of NMBA in
patients with ARDS remains unclear. Some authors
suggest that NMBA could decrease lung and systemic
inflammation [8]. Also, a brief period of paralysis may
facilitate lung protective mechanical ventilation by im-
proving patient–ventilator synchrony and allowing for
the accurate adjustment of tidal volume and pressure





































*Unclear allocation concealment in two studies, not analyzed using intention-to-trerelated alveolar collapse and regional alveolar pressure
increases with overdistention [3]. We showed in our
meta-analysis that patients treated with NMBA were
ventilated with similar tidal volumes of patients not
treated with NMBA, however, the plateau pressure in
patients under NMBA showed a higher decrease over
time. Finally, it may be necessary to paralyze patients to
tolerate hypercapnic acidosis when a lower tidal volume













t Unlikely 0.71 (0.55 – 0.90) 27% +++,
moderate
t Unlikely 0.68 (0.51 – 0.92) 23.7% +++,
moderate
t Unlikely 0.45 (0.22 – 0.92) 0% +++,
moderate
t Unlikely 1.13 (0.76 – 1.67) 0% +++,
moderate
at in one studies.
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sonable to think that patient under NMBA uses more
sedation than controls [3]. The only study that assessed
this topic showed no difference of duration of sedation
with sufentanil and midazolam in patients treated with
NMBA and controls [7]. Instead, control patients used
sedation for a median of 13 days vs. 6 days in patients
treated with NMBA, and this may have happened be-
cause the improvement in oxygenation observed in
patients treated with NMBA may have allowed an earlier
reduction of sedation.
The main safety concern with the use of a NMBA is
muscle weakness since several studies suggest that the
long-term administration of NMBAs may be associated
with the development of neuromuscular weakness in
critically ill patients. Cisatracurium appears to be the
safer compound, once the occurrence of myopathy is
less common than with amino-steroid compounds [10].
We found similar incidence of critical illness neuromyo-
pathy between the groups however, no study performed
electromyography exam in the patients. Indeed, the dur-
ation of mechanical ventilation was not increased in the
NMBA group, and the short duration of use of the
NMBA probably explains this finding.
These reported findings should be viewed within the
context of the limitations of this study and the research
in the field. The main limitation is that all studies ana-
lyzed were conducted by the same group of researchers
which can make the results biased. However, the largest
study was a multicenter trial that included 20 distinct
ICUs, reducing the chance of biases. In addition, another
limitation of our meta-analysis is that it is dominated by
the largest randomized controlled trial by Papazian et al
[3]. Another important concern is that the largest trial
analyzed did not assessed the effectiveness of the neuro-
muscular blockade with train-of-four stimulation, so we
cannot be sure that patients were adequately blocked
[11]. Finally, the Medical Research Council scale method
used to evaluate muscle weakness was limited to 28 days
(or to discharge from the ICU), a duration that may be
too brief to recognize muscle weakness in patients who
require prolonged mechanical ventilation, particularly if
they are slow to awaken [12].Conclusion
In conclusion, our meta-analysis demonstrated benefit of
use of NMBA early in the course of ARDS without in-
creasing the incidence of critical illness neuromyopathy.
These findings needs to be assessed with caution since
the studies evaluated came from the same group.Competing interests
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